V
Vasily Isakov
Researcher at Russian Academy
Publications - 82
Citations - 1214
Vasily Isakov is an academic researcher from Russian Academy. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 13, co-authored 70 publications receiving 1011 citations.
Papers
More filters
Journal ArticleDOI
World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Douglas R. LaBrecque,Zaigham Abbas,Frank Anania,Peter Ferenci,Aamir G. Khan,Khean-Lee Goh,Saeed Hamid,Vasily Isakov,Maribel Lizarzábal,Manuel M. Peñaranda,Juan F.R. Ramos,Shiv Kumar Sarin,Davor Štimac,Alan B. R. Thomson,Muhammed Umar,Justus Krabshuis,Anton LeMair +16 more
TL;DR: Review Team, Douglas R.R. LaBrecque,MD, FACP (chair, USA), Zaigham Abbas, MD, MBBS, FCPS, F RCP, FRCPI,FACP, FACG, AGAF (Pakistan), Frank Anania, MD; Peter Ferenci, MD (Austria), and Anton LeMair,MD (Netherlands)
Journal ArticleDOI
Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
Stefan Schreiber,Brian G. Feagan,Geert R. D'Haens,Jean-Frederic Colombel,Karel Geboes,Mikhail Yurcov,Vasily Isakov,Oleg Golovenko,Charles N. Bernstein,Diether Ludwig,Trevor A. Winter,Ulrich Meier,Chan Yong,Jürgen Steffgen +13 more
TL;DR: There was no evidence for clinical efficacy of BIRB 796 in CD, and a remarkable difference in the course of CD exists between Russia and non-Russian centers.
Journal ArticleDOI
Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
Christoph Sarrazin,Vasily Isakov,Evguenia S. Svarovskaia,Charlotte Hedskog,Ross Martin,Krishna Chodavarapu,Diana M. Brainard,Michael D. Miller,Hongmei Mo,Jean-Michel Molina,Mark S. Sulkowski +10 more
TL;DR: This work investigated the prevalence of late recurrent viremia and used refined phylogenetic analysis of multiple HCV genes to distinguish virologic relapse from reinfection and implications for determining true treatment efficiency and selecting optimal retreatment strategies.
Journal ArticleDOI
Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide.
Neil D. Shah,Meritxell Ventura-Cots,Meritxell Ventura-Cots,Juan G. Abraldes,Mohamed Alboraie,Mohamed Alboraie,Ahmad Alfadhli,Josepmaria Argemi,Josepmaria Argemi,Ester Badia-Aranda,Enrique Arús-Soler,A. Sidney Barritt,Fernando Bessone,Marina Biryukova,Flair José Carrilho,Marlen Castellanos Fernández,Zaily Dorta Guiridi,Mohamed El Kassas,Teo Eng-Kiong,Alberto Queiroz Farias,Jacob George,Wenfang Gui,Prem Harichander Thurairajah,John Chen Hsiang,Azra Husic-Selimovic,Vasily Isakov,Mercy Karoney,Won Kim,Johannes Kluwe,Rakesh Kochhar,Narendra Dhaka,Pedro Miguel Marques da Costa,Mariana A. Nabeshima Pharm,Suzane K. Ono,Daniela Reis,Agustina Rodil,Caridad Ruenes Domech,Federico Sáez-Royuela,Christoph Scheurich,Way Siow,Nadja Sivac-Burina,Edna Solange Dos Santos Traquino,Fatma Some,Sanjin Spreckic,Shiyun Tan,Julio Vorobioff,Andrew Wandera,Pengbo Wu,Mohamed Yacoub,Ling Yang,Yuanjie Yu,Nerma Zahiragic,Chaoqun Zhang,Helena Cortez-Pinto,Ramon Bataller,Ramon Bataller +55 more
TL;DR: In a cross-sectional analysis of patients with liver disease worldwide, it is found that patients with ALD are seen with more advanced-stage disease than patients with HCV-associated liver disease.
Journal ArticleDOI
Furazolidone‐based triple ‘rescue therapy’ vs. quadruple ‘rescue therapy’ for the eradication of Helicobacter pylori resistant to metronidazole
TL;DR: The optimal treatment of patients with Helicobacter pylori resistant to metronidazole with or without antibiotics has not been established and further research is needed to establish a treatment strategy.